Apellis Pharmaceuticals I...

24.28
0.00 (0.00%)
At close: Mar 28, 2025, 3:59 PM
23.97
-1.26%
Pre-market: Mar 31, 2025, 04:34 AM EDT

Company Description

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology.

In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver.

It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases.

Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. logo
Country United States
IPO Date Nov 9, 2017
Industry Biotechnology
Sector Healthcare
Employees 705
CEO Dr. Cedric Francois M.D., Ph.D.

Contact Details

Address:
100 Fifth Avenue
Waltham, Massachusetts
United States
Website https://www.apellis.com

Stock Details

Ticker Symbol APLS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001492422
CUSIP Number 03753U106
ISIN Number US03753U1060
Employer ID 27-1537290
SIC Code 2834

Key Executives

Name Position
Dr. Cedric Francois M.D., Ph.D. Co-Founder, President, Chief Executive Officer & Director
Timothy E. Sullivan Chief Financial Officer & Treasurer
Alec Machiels J.D., MBA Co-Founder & Director
David O. Watson Esq., J.D. General Counsel
Dr. Caroline R. Baumal M.D. Chief Medical Officer
Dr. Pascal Deschatelets Ph.D. Co-Founder & Chief Scientific Officer
James G. Chopas CPA Vice President, Corporate Controller & Chief Accounting Officer
Meredith Kaya Senior Vice President, Investor Relations & Strategic Finance
Prof. Peter Hillmen M.D., Ph.D. Head of Hematology Engagement & Member of PNH Scientific Advisory Board
Victoria L. Brown Senior Vice President

Latest SEC Filings

Date Type Title
Mar 18, 2025 4 Filing
Mar 06, 2025 4 Filing
Feb 28, 2025 S-8 Filing
Feb 28, 2025 10-K Annual Report
Feb 12, 2025 4 Filing
Feb 10, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 03, 2025 SCHEDULE 13G Filing
Jan 30, 2025 4 Filing
Jan 30, 2025 4 Filing
Jan 30, 2025 4 Filing